Background: Methylenetetrahydrofolate Reductase (MTHFR) is the key enzyme of xenobiotic detoxification, involved in the metabolism of anticancer drugs. Genotyping of the polymorphism MTHFR allows to make prognosis of chemotherapy side effects in different patients, personalize pharmacotherapy. Methods: QTc interval and myocardial systolic and diastolic function of 100 patients with breast cancer stages T1-3N0-3M0 treated with neo/adjuvant anthracycline chemotherapy were investigated. In the main study group 50 patients received cardioprotective medications (enalapril 2.5 mg orally twice daily and carvedilol 6.25 mg orally twice daily). The polymorphisms of MTHFR gene in control group were evaluated using Real-Time PCR. Statistica10.0 software was used to perform analysis of variance. Results: It was established that the specific manifestations of early cardiotoxicity of doxorubicin at a cumulative dose 300 mg/m 2 were QTc prolongation over 460 msec in the main group in 5 (10%) patients, in the control group À 13 (26%) patients, as well as diastolic dysfunction (DD) of the left ventricle type 1 in the main group in 5 (10%) patients, in the control group À 15 (30%) patients.The absence of cardioprotective therapy in our study was a risk factor for these complications: QTc interval prolongation (OR ¼ 3.15, 2.05 À 4.21, p ¼ 0.03) and DD (OR ¼ 3.85, 2.75 À 4.96, p ¼ 0.01).A molecular genetic analysis had shown that QT prolongation and DD were detected in 36.4% of patients with T/T genotype, in 36.6% À with C/T genotype and only 9.1% patients with genotype C/C. The risk of cardiotoxicity of chemotherapy in patients with breast cancer, which is the carrier of one or two mutant alleles of the gene MTHFR (genotype C/T and T/T) is 2.68 times higher (OR ¼ 2.68; 95% CI ¼ 1.24 À 5.78; p < 0.01) in comparison with carriers of genotype C/C. Conclusions: It is reasonable to determine the MTHFR gene polymorphism in patients with early breast cancer prior to treatment which allow to identifying a high-risk cardiotoxicity group for timely and adequate cardioprotective therapy administration. Legal entity responsible for the study: National Cancer Institute, Kiev, Ukraine. Funding: National Cancer Institute, Kiev, Ukraine. Disclosure: All authors have declared no conflicts of interest. Breast Clinic, Subang Jaya Medical Centre, Subang Jaya, Malaysia
Background: Pre-existing CVD risk factors in women with breast cancer increases their risk of developing adjuvant therapy induced cardiotoxicity. We measured the prevalence of major CVD risk factors in women newly diagnosed with breast cancer in a multiethnic setting. Methods: From 2015 to 2017, 2159 women with newly diagnosed invasive breast cancer were consecutively recruited from four tertiary hospitals in Malaysia. Demographic, medical and drug history were collected through interviews and verified with medical records. Pre-treatment height, weight, blood pressure, serum glucose, and cholesterol levels were measured. Risk of cardiotoxicity was estimated using the Cardiotoxicity Risk Score proposed by Herrmann, et al. Results: Median age at diagnosis was 54 years. Median tumor size at presentation was 2.7 cm and 54% had node-negative disease. A majority (70%) of patients had estrogen receptor positive tumors. Prevalence of hypertension was 43%, while hypercholesterolemia was found in 48%. Seventeen percent of patients had diabetes mellitus and 19% were obese. Only 2% were current smokers. Four percent of patients had pre-existing coronary heart disease, arrhythmias or valvular disease. Overall, 40% of patients presented with two or more major CVD risk factors (clustering). The clustering of CVD risk factors was substantial across all age groups; age < 40 years: 16%, 40-49 years: 24%, 50-64 years: 46%, > ¼65 years: 62%. The Malay and Indian patients were twice more likely to have CVD risk clustering than the Chinese. Of 1880 patients with non-metastatic breast cancer, 45% were planned for anthracycline-based chemotherapy, and 54% for adjuvant radiotherapy. Taking the adjuvant treatment plan into account, it appeared that approximately one in two women with breast cancer in our settings were at high risk of developing cardiotoxicity. Conclusions: Our findings highlight the need to accelerate the establishment of coordinated partnerships between the oncology and cardiology specialties to improve cardiac outcomes following breast cancer. In the era of precision medicine, these findings also lend support to the notion that the next generation adjuvant therapy decision-making tools in breast cancer should incorporate data on major CVD risk factors. Legal entity responsible for the study: Nirmala Bhoo-Pathy. Baker Heart and Diabetes Institute, Baker Heart and Diabetes Institute, Melbourne, Australia
Background: Cardiovascular disease (CVD) is the leading cause of death worldwide. With improved cancer treatment and survivorship, CVD and other non-cancer events compete with cancer as the underlying cause of death. However, their mortality risk in competing risk settings is not well characterised. Methods: We identified 21,637 individuals with a first cancer registered between January 2006 and December 2013 in the population-based Tasmanian Cancer Registry, Australia. Cumulative incidence functions were applied to assess the cumulative incidence of deaths due to specific competing events with follow-up to December 2015. Standardised mortality ratios (SMRs) and absolute excess risks (AERs) for non-cancer deaths were calculated to allow comparison with the general population.
Results: Overall, 8,844 deaths were observed with 1,946 (22.0%) from competing events (332 from subsequent cancer, 741 from CVD and 873 from other non-cancer events). The cumulative incidence of deaths due to CVD increased significantly with age at first cancer diagnosis (5-year cumulative mortality by age group: 15-64y -0.7%; 65-74y -2.1%; 75-84y -6.0%; 85þy -13.1%) and exceeded other competing events for those with a first cancer diagnosis at age 65 years or older. For the whole follow-up period, CVD deaths were as expected for the general population (SMR, 0.97; 95%CI 0.90-1.04), however within the first follow-up year, CVD deaths were more common than expected (SMR, 1.44; 95%CI 1.26-1.64; AER, 36.8/10,000 person-years). The SMR and AER for CVD deaths varied by first cancer sites showing an increased risk after a first diagnosis of lung cancer, haematological malignancies and urinary tract cancers. For other non-cancer events, the SMRs significantly increased for infectious disease and respiratory disease for the whole follow-up and within the first year of diagnosis.
Conclusions: CVD was the leading cause of competing mortality among Tasmanian cancer patients diagnosed from 2006-2013. The higher than expected risk of death due to CVD and other non-cancer events was greatest during the first year after cancer diagnosis highlighting the importance of early preventive interventions. ). Most common symptom was swelling of the extremity(54%) followed by pain(32%) and dyspnea (12.6%). Lower extremity (77.4%) thrombosis was more common than upper extremity thrombosis (9.8%). Breast cancer (n ¼ 37, 18.9%) had the most number of VTE, followed by lung (n ¼ 31, 15%). Gynecologic malignancies had up to 21.5%, followed by gastrointestinal malignancies 21.5% (n ¼ 44). Most patients had prior hospitalization (n ¼ 146, 71.5%) within the past three months prior to the diagnosis of VTE. Up to 81.8% (n ¼ 167) had no VTE prophylaxis while 9.8% (n ¼ 20) had primary prophylaxis prior to the occurrence of VTE. However, among those who had prophylaxis with heparin, two had no prior hospitalization for three months prior to the VTE diagnosis, and mostly had gynecologic malignancy, breast cancer, and hepatocellular cancer. Seventy percent of them had normal BMI and were mostly <65 years of age. Conclusions: Cancer patients still develop VTE even with primary prophylaxis and no hospitalization for the past three months which were the leading risk factors for developing VTE in prior studies. There is no difference in patient profile for those who received primary prophylaxis in our center compared to the general profile. Legal entity responsible for the study: Agnes Gorospe. Funding: Has not received any funding. Disclosure: The author has declared no conflicts of interest.
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